On July 29, 2020 The Board of Directors of McKesson Corporation (NYSE:MCK) reported a regular dividend of 42 cents per share of common stock (Press release, McKesson, JUL 29, 2020, View Source [SID1234562525]). The dividend will be payable on October 1, 2020, to stockholders of record on September 1, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On July 29, 2020 Exelixis, Inc. (Nasdaq: EXEL) reported that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 after the markets close. At 5:30 p.m. EDT / 2:30 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update (Press release, Exelixis, JUL 29, 2020, View Source [SID1234562524]). Access to the event is available via the Internet from the company’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 855-793-2457 (domestic) or 631-485-4921 (international) and provide the conference call passcode 6548897 to join by phone.

A telephone replay will be available until 8:00 p.m. EDT on August 8, 2020. Access numbers for the telephone replay are: 855-859-2056 (domestic) and 404-537-3406 (international); the passcode is 6548897. A webcast replay will also be archived on www.exelixis.com for one year.

On July 29, 2020 The Pancreatic Cancer Action Network (PanCAN) and GeneCentric Therapeutics, Inc. reported that they have entered into a collaborative research partnership for the advancement of RNA-based molecular signatures for pancreatic cancer disease progression and drug response (Press release, GeneCentric Therapeutics, JUL 29, 2020, View Source [SID1234562523]). The collaboration will combine GeneCentric’s single patient RNA-based report, including its Pancreatic Cancer Subtype Profiler (PurIST) for subtyping pancreatic ductal adenocarcinoma tumors (PDAC), with PanCAN’s extensive collection of patient molecular and outcomes data generated through its scientific and clinical programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"GeneCentric is advancing promising molecular signatures of disease progression and drug response in pancreatic cancer based on tumor subtyping through next generation RNA sequencing of the tumor and tumor/immune microenvironment, and immunogenomics," said Dr. Lynn Matrisian, Chief Science Officer of PanCAN. "The collaboration, which will involve profiling and data analyses from our Know Your Tumor program and Precision PromiseSM adaptive clinical trial, is designed to advance our goals of improving treatment responses and survival of PDAC patients, accelerating the development of novel therapies and defining potential curative strategies for people diagnosed with this devastating disease."

"PanCAN, with its leading-edge, innovative research programs to accelerate new therapies to the clinic and dramatically improve treatment options for pancreatic cancer patients, is an ideal partner for GeneCentric," said Dr. Mike Milburn, President and CEO of GeneCentric. "We are honored to work with the PanCAN team and their renowned collaborators to advance and apply novel molecular signatures to support landmark initiatives such as the Precision Promise study as well as other pivotal research in the pursuit of cures for patients."

The collaboration will involve two research projects and is focused on GeneCentric’s single patient molecular report, including two PurIST defined PDAC subtypes, Basal (gemcitabine/nab-paclitaxel responsive) and Classical (FOLFRINOX responsive). One study, aimed at the molecular characterization of potential treatment response, will be a retrospective analysis of patient data from the Know Your Tumor Program at diagnosis and treatment outcome. The second initiative is in conjunction with PanCAN’s Precision PromiseSM clinical trial to assess molecular signatures of patients at enrollment and association with treatment responses. The three-year study will enable application of the range of GeneCentric’s current PDAC as well as pan-cancer tumor and immunogenomic signatures of treatment response, as well as exploration of novel PDAC-related signatures.

On July 29, 2020 Akoya Biosciences, Inc., The Spatial Biology Company, reported a collaboration with UCSF Helen Diller Family Comprehensive Cancer Center (Press release, Akoya Biosciences, JUL 29, 2020, View Source [SID1234562522]). Scientists at UCSF Helen Diller Family Comprehensive Cancer Center have chosen Akoya’s Phenoptics multiplex immunofluorescence platform for developing predictive and prognostic biomarkers, particularly for use in selecting the most effective neoadjuvant and adjuvant immunotherapies for patients with early breast cancer. Click here to view a multimedia version of the press release, including media-ready images, downloadable resources, and more.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At UCSF, this collaboration will be led by Michael Campbell, PhD, and Laura Esserman, MD, MBA. Dr. Campbell is an immunologist who has worked in partnership with Dr. Esserman to better understand how to optimize immunotherapy. He is driving the work on the Phenoptics platform to develop predictors of response to the immuno-oncology drug combinations, and to use these insights to develop more effective combinations. Together they are working both on high risk invasive breast cancer and high-risk ductal carcinoma in situ (DCIS).

Dr. Esserman is a professor in the departments of Surgery and Radiology who co-leads the breast oncology program at the UCSF Helen Diller Family Comprehensive Cancer Center, and is the Principal Investigator of the I-SPY Trials, sponsored by the Quantum Leap Healthcare Collaborative. Following extensive evaluation of biomarker testing methods, Dr. Esserman and her team have standardized biomarker discovery and development efforts on the Phenoptics platform to measure as many as six markers at a time on a single pathology slide using multiplex immunofluorescence. The Phenoptics platform is the chosen platform for the I-SPY Trials.

"There is a clear need for biomarkers to guide both the choice and assessment of immune targeted combinations for high risk early-stage cancers, where opportunities for cure are much greater," said Dr. Esserman. "We believe that multiplexed immunofluorescence will lead to robust, predictive assays, because it enables better understanding of the cell-level biology underlying disease progression and response to therapy, by revealing the spatial arrangements and interactions of cells in the tumor microenvironment."

Immunotherapies harness the immune system to fight cancer and are increasingly being used in the early high-risk setting. The partnership’s goals are to make these therapies more effective and to understand the immune response, key to making them work for more patients. There is an urgent need for biomarkers that more accurately predict which patients will respond to a particular therapy. Multiplex immunofluorescence preserves critical spatial data about cell proximity and interaction in the tumor microenvironment, with the potential to provide higher predictive power compared to other biomarker approaches. Akoya’s Phenoptics platform provides an end-to-end solution for discovery research and clinical trials with the reproducibility, sensitivity and throughput needed to develop new biomarkers and has become the standard for biomarker-based clinical trials and translational research.

Cliff Hoyt, Vice President of Translational and Scientific Affairs at Akoya, commented: "Dr. Esserman is well known for her substantial achievements in characterizing the tumor microenvironment and treating breast cancers and it is an honor for our team to collaborate with her lab. With Dr. Esserman’s focus on practical and effective steps to improve drug development and the standard of care, we believe that this collaboration will have a real impact on patient treatment in the coming years."

On July 29, 2020 Sema4, a patient-centered health intelligence company, reported that funds managed by BlackRock led its oversubscribed Series C financing of $121 million at a post-money valuation of over $1 billion (Press release, Sema4, JUL 29, 2020, View Source [SID1234562521]). Additional new investors include Deerfield Management Company and Moore Strategic Ventures. Sema4’s Series C financing comes after achieving significant milestones following its first round of external financing (Series B) in which the company raised just over $120 million less than 12 months ago. Each of the investors from Sema4’s first round of external funding participated in this second round, including Blackstone, Section 32, Oak HC/FT, Decheng, and Connecticut Innovations. Sema4 was spun out of the Mount Sinai Health System in June 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of this announcement, Andrew Elbardissi, MD Partner at Deerfield, has joined Sema4’s board of directors. Sema4 has also recently added Mike Pellini, MD from Section32 (former CEO of Foundation Medicine), Rachel Sherman (former Principal Deputy Commissioner at the FDA), and Marty Chavez (former CFO of Goldman Sachs) to its board.

William Abecassis, Head of Innovation Capital at BlackRock, said: "Sema4 is a leader at the forefront of one of the most exciting intersections in healthcare – the application of technology, AI and machine learning to help improve patient outcomes. We are excited to support this talented management team as Sema4 begins its next phase of growth."

Andrew Elbardissi, MD Partner at Deerfield, commented: "Among their peer-group companies, Sema4 rises above the rest with its incredible team of innovators, relentless pursuit of better technology, and bone-deep commitment to reimagining what’s possible in healthcare. I am delighted to help them move forward on this path."

"This investment is exciting for the significant financial resources it provides Sema4 for our continued rapid growth and accelerated investment, and also for the world-renowned partners it brings to our team," said Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4. "I look forward to working with our new and existing investors — who collectively have deep expertise in the life and data sciences — as we create cutting-edge precision medicine solutions for providers and patients to dramatically improve health outcomes."

Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories. The company began with an emphasis on reproductive health and recently launched Sema4 Signal, a family of products and services providing data-driven precision oncology solutions. Over the last several months, Sema4 has also joined the fight against COVID-19. Sema4 has integrated its premier clinical and scientific expertise with its cutting-edge digital capabilities to deliver a holistic testing program that enables organizations to make fast, informed decisions as they navigate COVID-19.

Sema4’s expertise in data science and predictive modeling serve as the foundation for Centrellis, the company’s innovative health intelligence platform. This powerful platform is designed to provide a more complete understanding of disease and wellness and to offer physicians deeper insight into the patient populations they serve.

Goldman Sachs & Co. LLC acted as exclusive placement agent for the financing, and Fenwick & West LLP acted as legal counsel to Sema4.